Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology was written by Johannes, Jeffrey W.;Almeida, Lynsie;Barlaam, Bernard;Boriack-Sjodin, P. Ann;Casella, Robert;Croft, Rosemary A.;Dishington, Allan P.;Gingipalli, Lakshmaiah;Gu, Chungang;Hawkins, Janet L.;Holmes, Jane L.;Howard, Tina;Huang, Jian;Ioannidis, Stephanos;Kazmirski, Steven;Lamb, Michelle L.;McGuire, Thomas M.;Moore, Jane E.;Ogg, Derek;Patel, Anil;Pike, Kurt G.;Pontz, Timothy;Robb, Graeme R.;Su, Nancy;Wang, Haiyun;Wu, Xiaoyun;Zhang, Hai-Jun;Zhang, Yue;Zheng, Xiaolan;Wang, Tao. And the article was included in ACS Medicinal Chemistry Letters in 2015.Product Details of 18213-75-7 This article mentions the following:
The canonical Wnt pathway plays an important role in embryonic development, adult tissue homeostasis, and cancer. Germline mutations of several Wnt pathway components, such as Axin, APC, and ss-catenin, can lead to oncogenesis. Inhibition of the poly(ADP-ribose) polymerase (PARP) catalytic domain of the tankyrases (TNKS1 and TNKS2) is known to inhibit the Wnt pathway via increased stabilization of Axin. In order to explore the consequences of tankyrase and Wnt pathway inhibition in preclin. models of cancer and its impact on normal tissue, the authors sought a small mol. inhibitor of TNKS1/2 with suitable physicochem. properties and pharmacokinetics for hypothesis testing in vivo. Starting from a 2-Ph quinazolinone hit I, the authors discovered the pyrrolopyrimidinone compound II (AZ6102), which is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows 5 nM Wnt pathway inhibition in DLD-1 cells. Moreover, compound II can be formulated well in a clin. relevant i.v. solution at 20 mg/mL, has demonstrated good pharmacokinetics in preclin. species, and shows low Caco2 efflux to avoid possible tumor resistance mechanisms. In the experiment, the researchers used many compounds, for example, 5-Amino-1-methyl-1H-pyrazole-4-carboxamide (cas: 18213-75-7Product Details of 18213-75-7).
5-Amino-1-methyl-1H-pyrazole-4-carboxamide (cas: 18213-75-7) belongs to pyrazole derivatives. An alternative way to synthesize multisubstituted pyrazoles is the Csingle bondH arylation of simple pyrazoles. Pyrazole rings have been used as core components of several leading non-steroidal anti-inflammatory drugs (NSAIDs) and antihypertensive drugs. It has also been found to be useful as a bifunctional ligand for metal catalysis.Product Details of 18213-75-7
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics